Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00329719 · ClinicalTrials.gov registry record · Phase 1
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 115
- Enrollment target
NCT00329719: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00329719 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 115 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00329719, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 115 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of temsirolimus when given together with sorafenib tosylate and to see how well they work in treating patients with glioblastoma that has come back. Sorafenib tosylate may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temsirolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib tosylate and temsirolimus may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving sorafenib tosylate with temsirolimus may kill more tumor cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Conventional Surgery
- DRUG Temsirolimus
- DRUG Sorafenib Tosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2006-03-24 |
| Est. Completion | 2013-02-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00329719
The ClinicalTrials.gov registry entry for NCT00329719 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00329719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00329719 about?
NCT00329719 is a clinical study titled "Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma". This phase I/II trial studies the side effects and best dose of temsirolimus when given together with sorafenib tosylate and to see how well they work in treating patients with glioblastoma that has come back. Sorafenib tosylate may stop the growth of tumor cells by blocking blood flow to the tumor....
What is the current status of trial NCT00329719?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 115 participants. The study started on 2006-03-24. Estimated completion is 2013-02-02.
What interventions are being tested in trial NCT00329719?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Conventional Surgery (PROCEDURE), Temsirolimus (DRUG), Sorafenib Tosylate (DRUG).
Who is sponsoring clinical trial NCT00329719?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.